Trial reportEuropean journal of nutrition2026
Efficacy of leucine-rich high protein supplementation on body composition and muscle function among older adults with sarcopenia: a randomized controlled trial.
Trial report in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Protein Consumption and Cognitive Health in Aging: Associations with Sarcopenia and Dietary Options, a Narrative Review.Nutrients · 2026Review
- Sarcopenic obesity and body composition phenotypes in older adults with chronic kidney disease: associations with estimated mortality risk.Scientific reports · 2026Article
- Associations of magnesium intake and a magnesium-rich diet score with sarcopenia in middle-aged and older Korean adults: potential mediation by C-reactive protein.Frontiers in nutrition · 2026Article
- Sarcopenia independently predicts acute cholecystitis in older patients with gallstones: a retrospective cohort study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of leucine-rich high protein supplementation on body composition, muscle function and gene expression among older adults with or at risk of sarcopenia residing in Klang Valley, Malaysia.
methodsA total of 47 participants were recruited into this 12-week double-blinded, randomized controlled trial. Intervention group consumed 2 sachets of high protein supplement daily contributing to 50.6 g of protein/day and 6 g of leucine/day. Control group received placebo supplement. Body composition was assessed via anthropometry measurements, bioelectrical impedance analysis (BIA), and magnetic resonance imaging (MRI) of left mid-thigh. Meanwhile, muscle function was assessed using short physical performance battery (SPPB). A total of 16 ml of full blood was collected pre- and post- study to assess participants' health profiling and changes in gene expression as determined by mitochondrial RNA activity derived from the peripheral blood mononuclear cells. The measurements were performed at 0, 6, and 12 weeks.
resultsParticipants were mostly women (89.4%) with a mean age of 69.3 ± 7.1 years. Repeated measures ANOVA showed no significant intervention effect in body composition (anthropometry measurements and BIA) as well as muscle function (SPPB score). However, genes responsible for adenosine triphosphate (ATP) production (GBA, MLYCD), cell proliferation (STAT5A) and DNA repair (BRCC3) were significantly up-regulated in intervention group (p < 0.05).
conclusionLeucine-rich high protein supplementation did not produce significant changes in body composition or muscle function in older adults with sarcopenia. However, it showed potential in improving gene expression. Further studies with a longer supplementation period and a larger sample size might be needed for noticeable changes, particularly for body composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.